Compare Adaptive Biotechnologies Corp (ADPT) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Norfolk Southern Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Norfolk Southern Corporation trades at $319.87 (market cap $72.49B). The key difference: Norfolk Southern Corporation is far larger — about 21.8× Adaptive Biotechnologies Corp's market cap, and Norfolk Southern Corporation pays a 1.67% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | NSC | |
|---|---|---|
Market Cap | $3.33B | $72.49B |
Sector | Health | Technology |
52-Week High | $22.37 | $325.68 |
52-Week Low | $10.24 | $259.49 |
Enterprise Value | $3.19B | $88.25B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Norfolk Southern (NSC) trades at $321.9, down 0.25% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $337. The stock shows strong profitability with a 21.91% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights the ongoing merger process with Union Pacific, a key regulatory and operational focus.
The outlook for NSC is cautiously optimistic, with potential upside from the merger and consistent earnings performance, but risks include regulatory hurdles for the merger and rich valuation multiples. Investors should weigh the strong cash flow generation against execution risks in a consolidating industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
